Earli

Senior Scientist, Bio AI

Earli  •  $205k - $235k/yr  •  Redwood City, CA (Onsite)  •  21 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.
64
AI Success™

Job Description

Earli is a BioAI therapeutics firm in Redwood City, California that programs cancer to turn against itself. Cancer cells become hyperlocal factories for potent immune therapies that are otherwise too toxic to be used systemically Earli AI-designs synthetic genetic switches that are intravenously injected but ONLY activate in cancer cells, using non-integrating DNA in a stealth LNP. Once activated, they force the cancer cells to produce encoded proteins – T cell engagers, cytokines, agonists – that activate the immune system to kill the cancer. The hyperlocal activation avoids on-target/off-tumor effects and drives up the therapeutic index. Instead of focusing on where the drug goes, Earli changes where the drug is produced

Who You Are

  • You share our same sense of dedication, scientific passion and entrepreneurial spirit
  • You work well in a fast-paced and extremely focused startup environment
  • You are not only smart, but clever and constantly think outside the box
  • You are able to make logical decisions in an instant when there is little time to evaluate
  • You are a natural communicator and relationship builder
  • You stay calm under high pressure and stress
  • You have the ability to multi-task in a serious way, with an extreme attention to detail
  • You become a representative of the core DNA of the company through who you are

The Position

Earli Inc. is currently seeking a top caliber Senior Scientist, Bio AI to join our Synthetic Bioengineering team.

Your Primary Responsibilities

  • Leverage cutting-edge ML, bioinformatics, and high-throughput assay data to design cancer-specific synthetic promoters and novel genetic medicines that will directly impact Earli’s clinical pipeline.
  • Train generative AI models for designing genetic medicines by leveraging Earli’s proprietary Massively Parallel Reporter Assay (MPRA) data as well as external data sets
  • Contribute to wet lab experimental design and data evaluation to benchmark AI model performance against ground truth wet lab data and create a rapid iteration loop
  • Perform routine computational analyses to analyze MPRA and other large experimental datasets using existing packages as well as bespoke analysis where needed. Provide accessible interfaces (e.g. Shiny apps) for routine data analysis (e.g. RNAseq profiling) for team members
  • Perform routine bioinformatic analyses on multi-modal omics data (RNAseq and scRNA-seq, ATAC-seq, proteomics, phospho-proteomics etc.) using individual as well as coherent multi-omic ML-based pipelines to identify key dysregulated targets and pathways in selected cancer indications
  • Routinely deploy code and execute on Earli’s infrastructure hosted by Cloud Service Providers (e.g. GCP) with appropriate engineering adaptations as needed. Help develop and work within budgets for GPU usage/compute

Your Required Experience, Knowledge and Skill

  • Master’s or PhD degree in a relevant field (bioengineering, computer science, data science, etc.) with a minimum of 3 years of hands-on experience using AI/ML applied to genomic/bioinformatic data using state-of-the-art GenAI models
  • Deep, direct expertise (preferably with high-quality publications) in developing novel GenAI models trained on massive biological data. Hands-on expertise in model training, fine-tuning, and in silico evaluation is a pre-requisite for this role.
  • An expert level of competence in data analysis on large and complex empirical data, such as MPRA data, multi-modal omics data, etc.
  • Familiarity with and prior experience collaborating with wet lab scientists to generate and curate high-throughput screening data on large libraries of DNA or RNA sequences
  • Proficiency in routine bioinformatic analyses such as differential gene expression, ATAC-seq and RNA-seq analysis, etc.
  • Expert level coding skills in Python and R
  • Basic knowledge of fundamental cancer biology is required. Deep expertise in cancer -omics, biomarkers, targets and pathways is preferred
  • Excellent verbal and written communication as well as interpersonal skills are required
  • Able to multi-task, manage multiple projects simultaneously and work effectively within a team
  • Ability to think independently and fully integrate into a high achieving team environment

The base salary for this position is $205,000-$235,000 per year.

If interested in applying, please attach a detailed CV with research experience and publications listed; and have a well-developed LinkedIn and GitHub profile for us to assess your background.

We look forward to hearing from you!

If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.

We look forward to hearing from you!

Earli

About Earli

Earli mission is to make cancer a benign experience by turning cancer against itself.

Earli creates genetic constructs that turn on only in cancer cells and then re-program the cancer cells to produce their own therapies, to kill themselves.

Earli has been funded by Andreessen Horowitz's a16z Bio+Health Fund, Khosla Ventures, Perceptive Advisors, Sands Capital, Marc Benioff, Menlo Ventures, Accenture Ventures, Han River Partners (S Korea). Earli is based in Redwood City, California.

For decades, the vision has been dreamed about to one day “program disease cells to kill or cure themselves.” If disease cells could be taken control of, they could be forced to run “injected biologic programs” to attack themselves or activate the body’s immune system to fight the disease. Standing in the way is a fundamental unsolved questions in medicine: how to correctly distinguish healthy cells from disease cells. For cancer, many attempts have been made to “kill the bad cells while not killing the good ones.” The conventional approaches are still crude; they attack both cancers and patients, or don't produce any response at all.

Earli turns the approach to targeting cancer cells on its head. Based on original research at Stanford University and subsequent 7 years of research at Earli, the company has built programmable genetic constructs that can infiltrate any cells but use conditional logic inside the cell nucleus to determine if a cell is a cancer cell, or not. The construct switches on only in cancer cells, then forcing them to become "factories" that produce encoded proteins that activate the immune system to attack and ultimately kill the cancer. In essence, the cancer cells are forced to produce their own therapies.

Industry
Biotech & Life Sciences
Company Size
11-50 employees
Headquarters
Redwood City, California
Year Founded
2018
Website
earli.com
Social Media